Cite Filings / ORKA / 0000102909-26-000220
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13G

Statement of Beneficial Ownership

Oruka Therapeutics, Inc. · Filed 2026-01-30 · Acc 0000102909-26-000220

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2026-08-12 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-01-30 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-01-23 4 Chief Medical Officer acquired 32,500 shares (grant or award)
  • 2026-01-23 4 SVP, Finance acquired 17,500 shares (grant or award)
  • 2026-01-23 4 Chief Executive Officer acquired 76,700 shares (grant or award)
  • 2026-01-23 4 General Counsel acquired 32,500 shares (grant or award)
  • 2026-01-21 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G · T. Rowe Price Investment Management, Inc. 6.6%
  2. 2026-11-16 SCHEDULE 13G/A · RTW Investments, LP 4.7%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…